CMS Proposes Coverage For Colorectal Cancer Blood-Based Tests – Except For Epigenomics’ Screen
Executive Summary
The US Medicare agency coupled its proposed coverage memo on colorectal cancer screens based on blood-based biomarker tests with a note that the Epi proColon assay does not meet its criteria.
You may also be interested in...
Companies Find Growth Opportunities In Maturing Colorectal Cancer Blood-Based Screening Market
Companies making blood-based cancer screening tests face a number of barriers to full market entry but getting a foothold of any kind can be the start of a path towards greater ultimate uptake.
Epigenomics Request Triggers CMS Plan To Cover Colorectal Cancer Blood-Based Biomarker Tests
The US Centers for Medicare and Medicaid Services is considering a national coverage determination for a blood-based biomarker screening test for colorectal cancer after receiving a request for a national coverage determination from Epigenomics for its Epi proColon assay.
White House To Deliver 25 Million Face Masks To Low-Income Americans
The White House will be spending $86m to provide tens of millions of coronavirus masks to poorer American households.